This new approach using autologous MC as new cancer immunotherapy is premised on efficient, autologous production of MC, tumor targeting (using tumor-specific IgE or chimeric antigen strategies), and controllable MC degranulation leading to tumor-specific killing. This evidence concerns the gene IGHE and neoplasm.